In 2008, antiretroviral sales across the seven major markets totaled $10.7 billion, growing at a CAGR of 12.8% between 2005 and 2008. Datamonitor expects this expansion to slow down. Despite drivers such as new product launches, earlier treatment initiation, decreasing mortality and an increase in HIV prevalence, a series of patent expiries will impact branded sales from 2011.
Reasons to Purchase
Understand the changing market dynamics of HIV drugs, success factors for leading brands and the commercial potential of late stage pipeline products
Assess the impact of events such as patent expiries and new product launches on individual brands and the overall antiretroviral market.
Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2008 to 2018.
(0 items)
